NASDAQ:INVA Innoviva (INVA) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free INVA Stock Alerts $15.37 +0.14 (+0.92%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$15.09▼$15.3750-Day Range$14.40▼$15.5452-Week Range$11.40▼$16.86Volume403,983 shsAverage Volume672,505 shsMarket Capitalization$971.85 millionP/E Ratio7.05Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Innoviva alerts: Email Address Ad Stansberry Research$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).Find out how to do right here in this free video. About Innoviva Stock (NASDAQ:INVA)Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Read More INVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INVA Stock News HeadlinesApril 24, 2024 | finance.yahoo.comInnoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024April 24, 2024 | businesswire.comInnoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024May 2, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…April 22, 2024 | finance.yahoo.comShould Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?March 8, 2024 | benzinga.comInsider Decision Unfolding At Innoviva: Pavel Raifeld Exercises OptionsMarch 4, 2024 | msn.comArmata enters $35M credit agreement with InnovivaFebruary 29, 2024 | finance.yahoo.comInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressFebruary 29, 2024 | businesswire.comInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressMay 2, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…February 28, 2024 | msn.com10 stocks you can bet on being inflation-proofFebruary 14, 2024 | finance.yahoo.comJim Simons Bolsters Position in Innoviva Inc with Recent AcquisitionFebruary 8, 2024 | morningstar.comInnoviva Inc INVAFebruary 6, 2024 | morningstar.comCosmo Pharmaceuticals NV COPNJanuary 25, 2024 | stocknews.com3 Lucrative Biotech Stock Buys for SuccessJanuary 8, 2024 | msn.comChart of the Day: Innoviva - Individual Investor FavoriteDecember 30, 2023 | finance.yahoo.comInnoviva's (NASDAQ:INVA) investors will be pleased with their 29% return over the last three yearsDecember 21, 2023 | uk.finance.yahoo.comInnoviva, Inc. (INVA) stock historical prices & data – Yahoo FinanceDecember 11, 2023 | stocknews.comAnalyzing the Bullish Opportunities of 3 Biotech StocksNovember 27, 2023 | msn.comInnoviva (INVA) Price Target Increased by 7.14% to 15.30November 18, 2023 | finance.yahoo.comInsider Sell Alert: Marianne Zhen Offloads Shares of Innoviva IncNovember 14, 2023 | finance.yahoo.comInnoviva, Inc. (NASDAQ:INVA) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?November 3, 2023 | finance.yahoo.comInnoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 MillionNovember 1, 2023 | finance.yahoo.comPositive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated GonorrheaNovember 1, 2023 | finance.yahoo.comInnoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressOctober 18, 2023 | finance.yahoo.comCalculating The Intrinsic Value Of Innoviva, Inc. (NASDAQ:INVA)October 9, 2023 | seekingalpha.comInnoviva: A Lot Of Moving PartsSeptember 19, 2023 | finance.yahoo.comInnoviva to Participate in the Cantor Global Healthcare ConferenceSee More Headlines Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/02/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CUSIP88338T10 CIK1080014 Webwww.inva.com Phone(650) 238-9600Fax650-827-8690Employees112Year Founded1996Profitability EPS (Most Recent Fiscal Year)$2.18 Trailing P/E Ratio7.00 Forward P/E RatioN/A P/E GrowthN/ANet Income$179.72 million Net Margins57.89% Pretax Margin62.52% Return on Equity30.37% Return on Assets15.70% Debt Debt-to-Equity Ratio0.66 Current Ratio9.03 Quick Ratio7.96 Sales & Book Value Annual Sales$310.46 million Price / Sales3.11 Cash Flow$3.53 per share Price / Cash Flow4.32 Book Value$10.66 per share Price / Book1.43Miscellaneous Outstanding Shares63,230,000Free Float62,342,000Market Cap$965.52 million OptionableOptionable Beta0.57 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Pavel Raifeld C.F.A. (Age 40)Chief Executive Officer Comp: $754.67kMs. Marianne Zhen CPA (Age 55)Chief Accounting Officer & Secretary Comp: $530.21kMr. Stephen Basso M.B.A. (Age 58)Chief Financial Officer Key CompetitorsVir BiotechnologyNASDAQ:VIROcular TherapeutixNASDAQ:OCULKiniksa PharmaceuticalsNASDAQ:KNSACureVacNASDAQ:CVACPhathom PharmaceuticalsNASDAQ:PHATView All CompetitorsInsiders & InstitutionsHussman Strategic Advisors Inc.Bought 63,000 shares on 5/2/2024Ownership: 0.266%Jennison Associates LLCBought 35,294 shares on 5/2/2024Ownership: 0.123%Principal Financial Group Inc.Bought 1,121 shares on 4/29/2024Ownership: 0.512%China Universal Asset Management Co. Ltd.Bought 4,762 shares on 4/29/2024Ownership: 0.019%Yousif Capital Management LLCSold 2,410 shares on 4/26/2024Ownership: 0.041%View All Insider TransactionsView All Institutional Transactions INVA Stock Analysis - Frequently Asked Questions How have INVA shares performed in 2024? Innoviva's stock was trading at $16.04 at the beginning of 2024. Since then, INVA stock has decreased by 4.2% and is now trading at $15.37. View the best growth stocks for 2024 here. Are investors shorting Innoviva? Innoviva saw a decline in short interest in March. As of March 31st, there was short interest totaling 11,330,000 shares, a decline of 13.0% from the March 15th total of 13,020,000 shares. Based on an average trading volume of 681,300 shares, the days-to-cover ratio is presently 16.6 days. Approximately 18.2% of the shares of the stock are sold short. View Innoviva's Short Interest. When is Innoviva's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our INVA earnings forecast. How were Innoviva's earnings last quarter? Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings results on Thursday, February, 29th. The biotechnology company reported $0.76 EPS for the quarter. The biotechnology company earned $85.84 million during the quarter. Innoviva had a trailing twelve-month return on equity of 30.37% and a net margin of 57.89%. What ETFs hold Innoviva's stock? ETFs with the largest weight of Innoviva (NASDAQ:INVA) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), Invesco Pharmaceuticals ETF (PJP), Harbor Health Care ETF (MEDI), ETC 6 Meridian Small Cap Equity ETF (SIXS), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Conductor Global Equity Value ETF (CGV), SPDR S&P Pharmaceuticals ETF (XPH) and Roundhill Acquirers Deep Value ETF (DEEP). What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). Who are Innoviva's major shareholders? Innoviva's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Denali Advisors LLC (0.52%), Principal Financial Group Inc. (0.51%), Hussman Strategic Advisors Inc. (0.27%), Los Angeles Capital Management LLC (0.22%), Allspring Global Investments Holdings LLC (0.18%) and Jennison Associates LLC (0.12%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline. View institutional ownership trends. How do I buy shares of Innoviva? Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INVA) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits4 Cryptos BETTER than BitcoinTrue Market InsidersThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.